Feinberg Stephen Has $15.55 Million Stake in Lantheus Holdings, Inc. (LNTH)
Feinberg Stephen trimmed its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 48.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 881,105 shares of the medical equipment provider’s stock after selling 840,000 shares during the quarter. Lantheus Holdings accounts for 4.8% of Feinberg Stephen’s portfolio, making the stock its 5th largest holding. Feinberg Stephen owned approximately 2.36% of Lantheus Holdings worth $15,552,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also bought and sold shares of the company. Systematic Financial Management LP acquired a new stake in Lantheus Holdings during the first quarter worth about $1,314,000. Royce & Associates LP bought a new position in Lantheus Holdings during the second quarter valued at about $4,896,000. Bank of New York Mellon Corp increased its stake in Lantheus Holdings by 6.3% during the first quarter. Bank of New York Mellon Corp now owns 68,473 shares of the medical equipment provider’s stock valued at $856,000 after acquiring an additional 4,084 shares during the period. FNY Partners Fund LP bought a new position in Lantheus Holdings during the first quarter valued at about $174,000. Finally, California Public Employees Retirement System raised its holdings in Lantheus Holdings by 29.2% in the 1st quarter. California Public Employees Retirement System now owns 77,800 shares of the medical equipment provider’s stock valued at $973,000 after acquiring an additional 17,600 shares in the last quarter. 84.35% of the stock is owned by institutional investors.
A number of analysts have commented on LNTH shares. Zacks Investment Research downgraded Lantheus Holdings from a “buy” rating to a “hold” rating in a research report on Wednesday, September 20th. BidaskClub lowered Lantheus Holdings from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 17th. Cantor Fitzgerald began coverage on Lantheus Holdings in a research report on Monday, July 17th. They set an “overweight” rating and a $22.00 price objective on the stock. Jefferies Group LLC restated a “buy” rating and set a $18.00 price objective on shares of Lantheus Holdings in a research report on Friday, June 30th. Finally, Credit Suisse Group upped their target price on Lantheus Holdings from $14.00 to $19.00 and gave the company a “neutral” rating in a research note on Wednesday, August 2nd. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $18.60.
In other news, Director David F. Burgstahler sold 230,685 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $17.25, for a total transaction of $3,979,316.25. Following the transaction, the director now directly owns 13,248 shares of the company’s stock, valued at $228,528. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Derace L. Schaffer sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 13th. The stock was sold at an average price of $17.50, for a total transaction of $262,500.00. Following the transaction, the director now directly owns 48,730 shares in the company, valued at $852,775. The disclosure for this sale can be found here. Insiders have sold 906,344 shares of company stock valued at $15,499,626 in the last three months. Insiders own 2.30% of the company’s stock.
Shares of Lantheus Holdings, Inc. (LNTH) traded down 0.28% during mid-day trading on Wednesday, hitting $17.95. 236,370 shares of the stock traded hands. Lantheus Holdings, Inc. has a one year low of $7.61 and a one year high of $18.25. The company’s 50 day moving average is $17.41 and its 200 day moving average is $17.41. The firm has a market capitalization of $670.43 million, a P/E ratio of 24.52 and a beta of 0.91.
Lantheus Holdings (NASDAQ:LNTH) last posted its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported $0.42 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.18. The firm had revenue of $88.83 million for the quarter, compared to analysts’ expectations of $80.56 million. Lantheus Holdings had a negative return on equity of 37.47% and a net margin of 8.44%. The company’s quarterly revenue was up 13.9% compared to the same quarter last year. During the same quarter last year, the business earned $0.24 EPS. On average, equities analysts expect that Lantheus Holdings, Inc. will post $1.12 EPS for the current fiscal year.
Lantheus Holdings Profile
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH).
Receive News & Stock Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related stocks with our FREE daily email newsletter.